Toxicological parameters of the drug based on Ornidazole and Levamisole hydrochloride
https://doi.org/10.31016/1998-8435-2022-16-4-421-431
Abstract
The purpose of the research is the study of pharmaco-toxicological properties of the Ornidazole- and Levamisole hydrochloride-based drug.
Materials and methods. The pharmaco-toxicological properties of the Ornidazole- and Levamisole hydrochloride-based drug were studied in the premises of the Laboratory of Preclinical Studies, Faculty of Veterinary Medicine, Stavropol State Agrarian University. Acute and chronic toxicity, and irritant effect of the drug was studied under the Guidelines for Preclinical Studies of Drugs (2012). Hematological studies of laboratory animals were performed with an automatic hematological analyzer, and biochemical studies of the blood serum were done with an automatic biochemical analyzer.
Results and discussion. It has been found that the Ornidazole- and Levamisole hydrochloride-based drug belongs to the Hazard Class 3 for the median lethal oral dose in accordance with GOST 12.1.007–76 as moderately hazardous substances; it does not have a pronounced subchronic toxicity or irritant effect. Multiple use of the active substance for 14 days does not cause significant changes in the clinical condition, or in hematological and biochemical profile of laboratory animals.
About the Authors
A. V. ButenkoRussian Federation
Butenko Alexander V., graduate student
12 Zootekhnichesky per., 355017, Stavropol
V. A. Orobets
Russian Federation
Orobets Vladimir A., Dr. Sc. Vet., Professor
12 Zootekhnichesky per., 355017, Stavropol
I. V. Kireev
Russian Federation
Kireev Ivan V., Dr. Sc. Biol., Professor
12 Zootekhnichesky per., 355017, Stavropol
References
1. Arguello-Garcia R., Leitsch D., Skinner-Adams T., Ortega-Pierres M. G. Drug resistance in Giardia: mechanisms and alternative treatments for giardiasis. Adv. Parasitol. 2020; 107: 201-282.
2. Canete R., Noda A. L., Rodriguez M. et al. 5-Nitroimidazole refractory giardiasis is common in Matanzas, Cuba and effectively treated by secnidazole plus high-do.se mebendazole or quinacrine: a prospective observational cohort study. Clin. Microbiol. Infect. 2019; 26 (8): 1092.е1-1092.е6.
3. Dobo B. Prevalence of intestinal protozoan infection among patients in Hawassa city administration millennium health center, Ethiopia. J. Appl. Biotechnol. Bioeng. 2018; 5 (4): 210-241. doi: 10.15406/jabb.2018.05.00139
4. Leitsch D. A review on metronidazole: an old warhorse in antimicrobial chemotherapy. Parasitology. 2019; 146: 1167-1178.
5. Mørch K., Hanevik K. Giardiasis treatment: an update with a focus on refractory disease. Curr. Opin. Inf. Dis. 2020; 33 (5): 355-364. doi: 10.1097/QCO.0000000000000668
6. National Center for Biotechnology Information. PubChem Compound Summary for CID 28061, Ornidazole. https://pubchem.ncbi.nlm.nih.gov/compound/Ornidazole. Accessed Jan. 29, 2022.
7. National Center for Biotechnology Information. PubChem Compound Summary for CID 26879, Levamisole. Retrieved January 30, 2022 from https://pubchem.ncbi.nlm.nih.gov/compound/Levamisole.
Review
For citations:
Butenko A.V., Orobets V.A., Kireev I.V. Toxicological parameters of the drug based on Ornidazole and Levamisole hydrochloride. Russian Journal of Parasitology. 2022;16(4):421-431. (In Russ.) https://doi.org/10.31016/1998-8435-2022-16-4-421-431